8-K: Verrica Pharmaceuticals Reports Q4 and Full Year 2024 Financial Results, Highlights YCANTH Growth and Pipeline Advancement

Verrica Pharmaceuticals announces its Q4 and full year 2024 financial results, showcasing growth in YCANTH dispensed applicator units and progress in its late-stage pipeline.

Summary

• Verrica Pharmaceuticals reported financial results for the fourth quarter and full year ended December 31, 2024.
• The company saw a 12.3% sequential quarterly growth in YCANTH dispensed applicator units in Q4 2024.
• Verrica's late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH).
• A $42 million public offering was completed in November 2024, strengthening the balance sheet.
• The company aims to achieve cash positive monthly operating results by the end of 2025.
• Product revenue for Q4 2024 was $0.3 million, compared to $1.9 million in Q4 2023, due to distributors using existing inventory.
• Product revenue for the full year 2024 was $6.6 million, compared to $4.7 million in 2023.
• The company reported a net loss of $16.2 million, or $0.24 per share, for Q4 2024, compared to a net loss of $24.6 million, or $0.53 per share, for the same period in 2023.
• The net loss for the full year 2024 was $76.6 million, or $1.48 per share, compared to a net loss of $67.0 million, or $1.48 per share, for the year ended December 31, 2023.
• As of December 31, 2024, Verrica had cash and cash equivalents of $46.3 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a net loss, there are positive developments such as growth in YCANTH sales, pipeline advancement, and cost reduction efforts. The potential for future revenue from milestones and warrant exercises also contributes to the positive outlook.

Positives

• YCANTH dispensed applicator units saw a 12.3% sequential quarterly growth in Q4 2024.
• The company successfully raised $42 million through a public offering in November 2024.
• Verrica is targeting cash positive monthly operating results by the end of 2025.
• VP-315 showed a 97% objective response rate in a post-hoc analysis of its Phase 2 study for basal cell carcinoma.
• Torii Pharmaceutical submitted a New Drug Application of TO-208 (YCANTH) for the treatment of molluscum in Japan.
• Verrica introduced a new single applicator configuration for YCANTH in Q1 2025 to meet growing demand and reduce costs.

Negatives

• Product revenue decreased in Q4 2024 to $0.3 million compared to $1.9 million in Q4 2023 due to distributors using existing inventory.
• The company incurred a net loss of $76.6 million for the full year 2024.
• Costs of product revenue increased to $1.9 million for the year ended December 31, 2024, compared to $0.3 million for the year ended December 31, 2023, partially due to obsolete inventory.
• The company recognized a returns reserve of $3.2 million for estimated returns from certain distributors due to lower than forecasted sell-through and product expiration.

Risks

• The company's cash and cash equivalents of $46.3 million as of December 31, 2024, may not be sufficient to fund operations for the one-year period following the release of the 2024 financial statements without additional funding.
• The company's ability to achieve cash positive monthly operating results by the end of 2025 is dependent on successful commercial execution and development of clinical assets.
• The company's future success depends on the successful development and commercialization of its product candidates, including YCANTH and VP-315.
• Market conditions and other risks and uncertainties described in Verrica's filings with the SEC could cause actual results to differ materially from forward-looking statements.

Future Outlook

Verrica aims to generate cash positive monthly operating results by the end of 2025 and advance its late-stage pipeline, including VP-102 (YCANTH) into a Phase 3 clinical trial for common warts as early as mid-2025.

Management Comments

• Dr. Jayson Rieger stated that the fourth quarter began a transition period for the company, and they have already achieved several substantial milestones.
• Dr. Rieger believes Verrica is now on track to successfully execute their turnaround strategy.
• Dr. Rieger's goal is to establish YCANTH as the standard of care for the treatment of molluscum contagiosum.

Industry Context

Verrica's focus on dermatology therapeutics aligns with the growing demand for treatments for skin diseases. The company's progress with YCANTH and its pipeline candidates positions it to address unmet needs in the market.

Comparison to Industry Standards

• Comparing Verrica's YCANTH to other molluscum treatments, it is the first and only FDA-approved product, giving it a competitive advantage.
• Other companies in the dermatology space, such as Castle Biosciences and DermTech, focus on different areas like skin cancer diagnostics, making direct comparisons challenging.
• Verrica's VP-315, targeting basal cell carcinoma, competes with established treatments like surgery and radiation, as well as newer therapies like hedgehog inhibitors; the 97% ORR in Phase 2 is promising but needs confirmation in Phase 3.
• When compared to other companies developing treatments for common warts, such as Cassiopea S.p.A. with its Winlevi product, Verrica's YCANTH has the potential to offer a novel approach.

Management Changes

Related Party Transactions

• Verrica recognized collaboration revenues related to supplies and development activity provided to Torii pursuant to the Torii Clinical Supply Agreement.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and future prospects.
• Employees were affected by the restructuring and headcount reduction.
• Patients benefit from the development and commercialization of new treatments for skin diseases.
• Physician practices benefit from the new single applicator configuration for YCANTH.

Next Steps

• Advance VP-102 (YCANTH) into a Phase 3 clinical trial for the treatment of common warts as early as mid-2025.
• Report genomic and immune response data from the Phase 2 trial of VP-315 and receive minutes from an end-of-phase 2 meeting in the first half of 2025.
• Continue to focus on establishing YCANTH as the standard of care for the treatment of molluscum contagiosum.
• Finalize plans for a co-sponsored global Phase 3 clinical program to develop VP-102 (YCANTH) for the treatment of common warts with Torii Pharmaceutical.

Key Dates